Understand FDA changes in terms of your exact products.
Product-level FDA monitoring, delivered to your inbox. Which of your products are affected — by name and ingredient — with the analysis and action items already written.
From: Policy Canary <alerts@policycanary.io>
Your Marine Collagen Powder — Action Required
March 4, 2026 · 7:14 AM
Marine Collagen Powder
The FDA cited three companies for identity-testing failures on marine-sourced collagen in the last 90 days. Your product's ingredient profile matches the cited substances. Lab protocols need updating.
Action Items
- Verify identity-testing protocols for marine collagen
- Request updated CoA from supplier
- Document compliance review for FDA inspection readiness
Deadline
Q2 2026
Source
21 CFR 111.75(a)(1)(ii)
THE DIFFERENCE
Every FDA action.
Matched to your products.
Not summaries — product intelligence. Each card shows what Policy Canary actually delivers to your inbox.
Email Intelligence
Intelligence delivered, not searched for
Every alert arrives in your inbox, scoped to your products — with the analysis and action items already written.
From: Policy Canary
Your Marine Collagen Powder — Action Required
Marine Collagen Powder
Identity-testing warning mapped to your ingredient profile.
Action required by Q2 2026
21 CFR 111.75(a)(1)(ii)
Ingredient Match
Matched by formula
We match FDA actions to your actual ingredients — not just product categories.
Matched to FDA Warning Letter WL-2025-1847
Speed
FDA to inbox in hours
Our pipeline ingests every publication the same day.
FDA publishes
Oct 14
Pipeline ingests
Oct 14
Your inbox
<24h
Dashboard
Every product at a glance
One view. All your products. Color-coded status.
Monitored Products
Marine Collagen Powder
BHA Eye Cream SPF 15
Biotin Complex 5000mcg
Coverage
7 FDA data sources
Federal Register, guidance documents, warning letters, import alerts, Regulations.gov, openFDA, and RSS — all in one pipeline.
Federal Register
847
Warning Letters
1,247
openFDA
169K
Guidance Docs
2,761
Import Alerts
154
Regulations.gov
1,178
RSS Feeds
12
WHEN YOU NEED TO DIG DEEPER
Your dashboard is here
when you need it.
The intelligence starts in your inbox. When you want to explore further — search enforcement history, manage products, see the full picture — your dashboard is ready.
app.policycanary.com/products
Monitored Products
Marine Collagen Powder
NovaBiotics failed identity testing for marine collagen. COA-only documentation was deemed insufficient by the FDA. Your product uses the same ingredient — this warning applies to your formulation.
Recommended Actions
- 1Audit identity testing protocols against 21 CFR 111.75(a)(1)(ii)
- 2Verify COA includes marine collagen-specific identity tests, not generic protein analysis
- 3Confirm per-batch testing with your contract manufacturer
Action required by Q2 2026
Source: FDA CFSAN Warning Letters · 21 CFR 111.75(a)(1)(ii)
Interactive demo · click any product to see its intelligence
WEEKLY INTELLIGENCE
The FDA This Week
May 25–May 29, 2026
Enforcement concentrated on drug manufacturing integrity and unapproved nasal sprays, with Warning Letters issued to Sato Pharmaceutical and Alchymars ICM SM for systemic CGMP failures. Food safety actions focused on pathogen risks in botanical supplements and pet food, while the agency reopened comment periods for removing solvents like benzene from additive regulations. Medical device alerts highlighted manufacturing defects in fluid delivery systems, specifically impacting ICU Medical tubing and Medline manifolds.
Deadline: 2026-07-15
View Source ↗Challenges and Solutions in Lot-Level Food Traceability; Public Meeting and Request for Comments
FDA is announcing a public meeting and soliciting comments to discuss the implementation of lot-level food traceability requirements. The meeting aims to address challenges and explore solutions related to the Food Traceability Rule, which requires additional recordkeeping for certain foods on the Food Traceability List (FTL) to aid in faster identification and removal of contaminated products from the market.
GSC Products, LLC — Unapproved New Drugs/Misbranded/OTC
GSC Products, LLC
FDA CDER issued a warning letter to GSC Products, LLC for marketing SINUS PLUMBER Headache Nasal Spray as an unapproved new drug and misbranded OTC drug. The product makes claims to relieve migraines, cluster headaches, and inflammation, which exceed the permitted uses under the relevant OTC monograph (M013). Additionally, its nasal route of administration and active ingredients—including feverfew, arnica montana, oleoresin capsicum, caffeine anhydrous, and peppermint oil—are not permitted for OTC internal analgesics without an FDA-approved application.
Sato Pharmaceutical Co., Ltd. — CGMP/Drugs/Adulterated/OTC
Sato Pharmaceutical Co., Ltd.
The FDA issued a Warning Letter to Sato Pharmaceutical Co., Ltd. for severe CGMP violations at their Tokyo drug manufacturing facility. Inspectors observed fundamental flaws in the aseptic filling line for sterile OTC drugs, including multiple media fill failures. Furthermore, the firm failed to maintain a proper stability testing program, omitting identification of product degradation impurities, and released OTC products to the U.S. market without conducting required microbiological testing for the Burkholderia cepacia complex pathogen. The firm must provide a comprehensive risk assessment, remediation plan, and maintain a halt on US-bound sterile drug production until corrective actions are completed.
Insulet Initiates Voluntary Medical Device Correction for Certain Omnipod® Pods in the U.S. and Affected International Markets
Insulet Corporation has issued a voluntary recall for specific lots of Omnipod 5, Omnipod DASH, and Omnipod Eros Pods due to a manufacturing defect. The issue involves a small tear in the cannula tubing that can cause insulin to leak outside the pod, leading to under-delivery. This poses a serious health risk, including high blood glucose and diabetic ketoacidosis (DKA). Approximately 7 million pods are affected globally, with 24 reported serious adverse events.
Don't miss the next briefing.
The weekly FDA digest for product teams. Free. No account required.
WHO IT'S FOR
You don't have a regulatory team.
You have Policy Canary.
Whether you're the founder, the quality lead, or the person who gets the call when something goes wrong — you need product-level answers, not regulatory summaries.
Founder / CEO
32 SKUs · 40+ active ingredients
“Which of my 32 SKUs is affected? I can’t cross-reference 40+ ingredients manually after every FDA notice.”
QA Manager
Moisturizer line · Next audit: Q2 2026
“Does the new BHA guidance apply to our moisturizer line? I need to know before our next audit.”
Product Manager
Q3 launch timeline · Collagen SKU at risk
“What does this collagen identity testing warning mean for our Q3 launch timeline?”
VP Regulatory
47 products · 3 categories
“I have 47 products. Show me which ones are affected — not a 500-page Federal Register summary.”
Don't find out from a recall notice.
Your Marine Collagen Powder. Your BHA Eye Cream. Monitored by name, matched by ingredient, matched against every FDA change.
Your products monitored by name and ingredient
Action items with deadlines, not summaries
Every claim linked to the source document
All-clear confirmation when nothing affects you
The FDA cut 3,859 employees. Enforcement is less predictable, not more.
7
FDA data sources
<24 hrs
pub to email
169K
substances indexed
How many products?
5Monthly Cost
$99
Included Products
5
Base Plan
Total: $99/mo
Includes 5 products
Full access included. No data caps. Cancel anytime.